Key Advances in Endometrial Cancer

EP. 1: Endometrial Cancer Incidence and Risk Classification

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

January 29th 2021

EP. 2: Genomic Assessments for Metastatic Disease

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

January 29th 2021

EP. 3: Treatment Challenges: Advanced Endometrial Cancer

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 4: Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 5: Second-Line Checkpoint Inhibitor for MSI-H Disease

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 6: GARNET Clinical Trial Regimen in Advanced Disease

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 7: Rationale for Combination Therapy in Advanced EC

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 8: Safety/Efficacy Results From EC Cohort of KEYNOTE-146

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 9: Impact of Pembrolizumab/Lenvatinib Approval in EC

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 10: Therapy Sequencing Through Multiple Lines of Therapy in EC

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 11: Novel Strategies in Development for EC Management

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 12: Promising Novel Targets for Endometrial Cancer Management

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

EP. 13: Case 2 Discussion and Considerations for Second-Line Treatment Selection

ByThomas Cluzeau, MD, PhD,Guillermo Garcia-Manero, MD,Rami D. Komrokji, MD,Sanam Loghavi, MD,Uwe Platzbecker, MD

February 16th 2023

The panelists discuss Dr Cluzeau’s presented case, emphasizing the importance of pathology reporting, and expand upon approaches to second-line treatment selection for patients with MDS-RS.

Key Advances in Endometrial Cancer

EP. 1: Endometrial Cancer Incidence and Risk Classification

EP. 2: Genomic Assessments for Metastatic Disease

EP. 3: Treatment Challenges: Advanced Endometrial Cancer

EP. 4: Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

EP. 5: Second-Line Checkpoint Inhibitor for MSI-H Disease

EP. 6: GARNET Clinical Trial Regimen in Advanced Disease

EP. 7: Rationale for Combination Therapy in Advanced EC

EP. 8: Safety/Efficacy Results From EC Cohort of KEYNOTE-146

EP. 9: Impact of Pembrolizumab/Lenvatinib Approval in EC

EP. 10: Therapy Sequencing Through Multiple Lines of Therapy in EC

EP. 11: Novel Strategies in Development for EC Management

EP. 12: Promising Novel Targets for Endometrial Cancer Management

EP. 13: Case 2 Discussion and Considerations for Second-Line Treatment Selection

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma

Five Under 5: Top Oncology Videos for the Week of 1/25